CDKN2B

CDKN2Bgene

CDKN2B variants affect vascular cell proliferation and inflammatory signaling, modulating atherosclerotic plaque development and rupture risk.

Pathway placement

Cascade stepPlaque inflammation

Confidencemedium

RationaleTop CAD susceptibility locus at 9p21.3 with arterial wall and vascular inflammation effects.

Also acts inLipid entry/oxidation

Druggability

DruggableNo

Known drugs / candidates0

Small-molecule tractableNo

Antibody tractableNo

EnsemblENSG00000147883

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-19.7

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Whole blood — gene is not a circulating analyte; measure protein product or genotype

Collection tube

K2-EDTA whole blood (lavender-top)

Method / principle

SNP genotyping / sequencing; or immunoassay of encoded protein

Reagent / substrate

Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein

Platform

qPCR / NGS / array

Turnaround · availability

Send-out · Genotyping widely available; protein assay variable

0.283

Open Targets association (acute_MI)